Summary
A phase-II trial of 4-demethoxydaunorubicin (4-DMDR) was performed in 21 patients with advanced renal cell carcinoma. The drug had demonstrated a broader spectrum of activity with less cardiotoxicity in preclinical evaluation than the parent compound daunorubicin. The starting dose was 12.5 mg/m2, with escalations to 15 and 17.5 mg/m2 in the absence of toxicity. Myelosuppression was the primary toxicity and cardiac toxicity was not seen in four patients who received four or more doses of DMDR. No responses were seen in 19 adequately treated patients, including 14 who had received no prior therapy.
This is a preview of subscription content, log in via an institution to check access.
References
Ahmed T, Needles B, Yagoda A, Watson R (1984) Phase II trial of 4′epi-doxorubicin in advanced measurable hypernephroma. Cancer Treat Rep (in press)
Arcamone F, Bernardi L, Giardino P, Patelli A, Di Marco A, Casazza A, Pratesi G, Reggiani P (1976) Synthesis and antitumor activity of 4-demethoxydaunorucibin, 4-demethoxy-7,9-diepidaunorubicin, and their beta anomers. Cancer Treat Rep 60:829–834
Berman E, Wittes Casper E, Gralla R, Young R (1983) Phase I trial of 4-demethoxydaunorucibin (4-DM). Proc Am Assoc Cancer Res 23:135
Bonfante V, Bonadonna G, Ferrar L, Villani F, Veronesi U (1983) Phase I study of 4-demethoxydaunoribicin(dm-DNR). Proc Am Assoc Cancer Res 23:138
Casazza A (1979) Experimental evaluation of anthracycline analogs. Cancer Treat Rep 63:835–844
Dimarco A, Zunio F, Casazza A (1978) Comarison of biochemical and biological methods in the evaluation of new anthracycline drugs. Antibiot Chemother 23:12–20
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Scher, H.I., Yagoda, A., Ahmed, T. et al. Phase-II trial of 4-demethoxydaunorubicin (DMDR) for advanced hypernephroma. Cancer Chemother. Pharmacol. 14, 79–80 (1985). https://doi.org/10.1007/BF00552731
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00552731